Ultra long-acting insulin approved for paediatric use

The once-daily basal insulin analogue Tresiba (insulin degludec) can now be used in children with diabetes.

Tresiba is a basal insulin for once-daily subcutaneous administration at any time of the day.
Tresiba is a basal insulin for once-daily subcutaneous administration at any time of the day.

Physicians can prescribe Tresiba to children and adolescents aged one to 17 with type I or type II diabetes.

The approval is based on efficacy and tolerability data from the BEGIN YOUNG 1 trial, which showed that insulin degludec given once daily in combination with insulin aspart (NovoRapid) maintained long-term glycaemic control in children and adolescents with type I diabetes.1

"When treating children and adolescents with diabetes, getting patients to target while minimising side effects is always a priority," said Dr Nandu Thalange, paediatric endocrinologist at Norfolk and Norwich University Hospital, Norwich, United Kingdom and the lead investigator of BEGIN YOUNG 1.

"This [approval] for insulin degludec offers patients between the ages of one and 17 a once-daily basal insulin which allows patients to get to target with a reduced risk of hyperglycaemia with ketosis versus insulin detemir."

Efficacy and safety

The BEGIN YOUNG 1 trial was a randomised, open-label 26-week treat-to-target trial comparing the efficacy and safety of insulin degludec (given once daily), and insulin detemir (Levemir; given once or twice daily), both in combination with bolus insulin aspart in children and adolescents with type I diabetes.1

Insulin degludec met the primary endpoint of non-inferiority to insulin detemir for mean change in HbA1c at 26 weeks (p<0.05). In a 26-week extension of the trial, patients who received insulin degludec achieved a lower insulin dose and a significantly greater reduction in fasting plasma glucose than those given insulin detemir (p<0.05).

The two regimens were associated with similar rates of overall, nocturnal, and severe hypoglycaemia although patients on insulin degludec had significantly lower rates of hyperglycaemia with ketosis (p<0.05). Patients’ weight remained unchanged with insulin detemir but increased with insulin degludec. Adverse event profiles were similar for insulin degludec and insulin detemir.1

Flexible dose timing

Insulin degludec has a duration of action exceeding 42 hours, allowing flexibility in day-to-day time of administration. In patients with type II diabetes, it can be administered alone or in combination with oral antidiabetic agents (including GLP-1 receptor agonists) and bolus insulin. In type I diabetes, Tresiba must be combined with rapid-acting insulin to cover mealtime insulin requirements.

Two strengths

Tresiba is available in two strengths: 100 units/ml and 200 units/ml. These are delivered in two distinct FlexTouch pen devices: the light green 100 units/ml pen, which delivers insulin in one-unit steps and the dark green 200 units/ml pen, which delivers insulin in two-unit steps. Prescribers should always specify the strength of Tresiba on the prescription and patients should visually identify the strength of Tresiba they are dispensed. 


  1. Thalange N et al. Long-term efficacy and safety of insulin degludec in combination with bolus insulin aspart in children and adolescents with type 1 diabetes. Diabetologia 2014; 57 (Suppl 1): S395.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases